Company intelligence / Profile preview

Sinobioway Cell Therapy

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Sinobioway Cell Therapy is advancing CAR-T cell therapies targeting EpCAM (for liver and stomach cancer) and CD19 (for acute lymphoblastic leukemia and diffuse large B-cell lymphoma), with lead candidates in Phase 2 clinical trials in China[4][9][8]. No recent efficacy data has been published in English since 2020; latest public info shows pending or ongoing Phase 2 trials.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapyGene therapyImmunotherapy
Industry: Biotech

Beyond the preview

Go deeper on Sinobioway Cell Therapy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinobioway Cell Therapy.

Explore the full profile